ARWR
HealthcareArrowhead Pharmaceuticals, Inc.
$63.88
$-3.91 (-5.77%)
Jan 5, 2026
Price History (1Y)
Analysis
Arrowhead Pharmaceuticals, Inc. is a healthcare company in the biotechnology industry with a significant scale, boasting a market capitalization of $8.83 billion, annual revenue of $829.45 million, and approximately 711 employees. The company's financial health appears mixed. While it has achieved a high gross margin of 100.0%, its operating margin stands at 17.2%. However, Arrowhead Pharmaceuticals reported a net loss of -$1,631,000 in the trailing twelve months, indicating challenges in profitability. The balance sheet shows substantial cash reserves of $917.47 million but also significant debt totaling $733.68 million. Arrowhead Pharmaceuticals' valuation metrics paint an inconsistent picture. With a forward P/E ratio of -14.12, it is essential to consider this metric cautiously. Additionally, the price-to-book ratio stands at 18.60 and the price-to-sales ratio is 10.65. The company's debt-to-equity ratio is high at 145.74, but its current ratio is relatively strong at 4.86.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Visit website →Key Statistics
- Market Cap
- $8.83B
- P/E Ratio
- N/A
- 52-Week High
- $72.36
- 52-Week Low
- $9.57
- Avg Volume
- 2.30M
- Beta
- 1.22
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 711